Boling Capital Completes Strategic Investment in Xianweide Bio to Advance Cell and Gene Therapies

Recently,Bio‑Link CapitalOfficially completed theBeijing Xianweide Biotechnology Center (Limited Partnership)(hereinafter referred to as “Xianweide Biotech”)strategic investment.

Xianweide Biotech isBeijing Xunsheng Biomedical Research Co., Ltd.(hereinafter referred to as “Xunsheng Medicine”) core shareholders. Xunsheng Medicine is a company thatCell and Gene TherapyAn innovative biopharmaceutical company centered on [core technology], specializing in the development of innovative Tumor-Infiltrating Lymphocyte (TIL) therapies and nucleic acid drugs (DNA and mRNA). It is a national industry standard-setting entity for TIL cells and HPV.Therapeutic VaccinesLeading Enterprise.

Bio‑Link Capital’s investment is based on the long-term value of the cellular immunotherapy sector, with a greater emphasis on Xunsheng Medicine inTumor Immunotherapytechnical accumulation in the field, as well as the clinical translation potential of its pipelines such as TIL therapy and therapeutic vaccines. Bio‑Link Capital will leverage “Capital + BD” dual-wheel drive model, providing financial support while leveraging Bio‑Link Capital’s global industry network to assist Xunsheng Medicine in connecting with overseas pharmaceutical companies, thereby accelerating the commercial licensing and collaboration of its pipeline.

Beijing Xunsheng Biomedical Research Co., Ltd. was established in March 2021, with its headquarters located in Daxing District, Beijing. The company is professionally dedicated to the development of innovative tumor-infiltrating lymphocyte (TIL) therapies and nucleic acid drugs. It has built a high-standard R&D headquarters and independently established a supporting quality management system.

In the field of tumor-infiltrating lymphocytes (TILs), leveraging its proprietary TILAmp cell expansion platform and LentiVae lentiviral gene modification platform, the company has developed a pipeline of first-in-class or best-in-class natural and genetically modified TIL products, demonstrating superior clinical efficacy and safety across various types of advanced solid tumors.ReT01It is the first natural TIL cell novel drug for cervical cancer developed with independent intellectual property rights in China, withoutQinglin, without the need for IL-2 injection.

In the field of nucleic acid therapeutics, the company leverages its proprietary engineered bacterial vector technology platform and sequence design platform to integrate synthetic biology and AI technologies into the development of therapeutic vaccine drugs. Its first DNA-based HPV therapeutic vaccine, AVL-101, has demonstrated best-in-class potential in preclinical animal studies and exploratory clinical trials. The company’s proprietary sequence optimization design and self-developed expression vectors outperform comparable domestic and international products under development in terms of efficacy, safety, and cost.

Bio‑Link Capital, a subsidiary of Suzhou Kelin Likang Pharmaceutical Technology, is a global platform for asset licensing transactions and investments focused on biopharmaceuticals and high-end medical devices. Centered on facilitating the international expansion of Chinese innovative drugs and introducing premium overseas assets, it has established a specialized cross-border business development (BD) team and launched China’s first interactive pharmaceutical asset trading platform.

Leveraging its global pharmaceutical partnership network spanning China and overseas markets, Bio‑Link Capital utilizes its professional business development capabilities and industry resources to facilitate the cross-border realization of value for innovative projects from R&D to commercialization.